Header Logo

Connection

Mindy Simpson to Hemophilia A

Back to Details
This is a "connection" page, showing publications Mindy Simpson has written about Hemophilia A.
Mindy Simpson
Connection Strength
6.522
Hemophilia A
  1. Using an educational intervention to assess and improve disease-specific knowledge and health literacy and numeracy in adolescents and young adults with haemophilia A and B. Haemophilia. 2021 Mar; 27(2):229-236.
    View in: PubMed
    Score: 0.725
  2. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 08; 121(8):1079-1086.
    View in: PubMed
    Score: 0.716
  3. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. J Manag Care Spec Pharm. 2020 Oct; 26(10):1258-1265.
    View in: PubMed
    Score: 0.701
  4. Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY?94-9027 for Severe Haemophilia?A: A Post Hoc Analysis. Adv Ther. 2020 06; 37(6):2763-2776.
    View in: PubMed
    Score: 0.688
  5. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.
    View in: PubMed
    Score: 0.675
  6. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost. 2018 04; 16(4):778-790.
    View in: PubMed
    Score: 0.593
  7. Management of joint bleeding in hemophilia. Expert Rev Hematol. 2012 Aug; 5(4):459-68.
    View in: PubMed
    Score: 0.401
  8. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 01; 16(1):39-43.
    View in: PubMed
    Score: 0.289
  9. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017 10 12; 130(15):1757-1759.
    View in: PubMed
    Score: 0.284
  10. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood. 2017 03 09; 129(10):1245-1250.
    View in: PubMed
    Score: 0.272
  11. Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A. Haemophilia. 2023 Sep; 29(5):1234-1242.
    View in: PubMed
    Score: 0.215
  12. Hemophilia: A Review of Perioperative Management for Cardiac Surgery. J Cardiothorac Vasc Anesth. 2022 01; 36(1):246-257.
    View in: PubMed
    Score: 0.176
  13. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia. 2017 Nov; 23(6):844-851.
    View in: PubMed
    Score: 0.144
  14. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. Cochrane Database Syst Rev. 2017 09 25; 9:CD011441.
    View in: PubMed
    Score: 0.143
  15. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Haemophilia. 2017 Nov; 23(6):832-843.
    View in: PubMed
    Score: 0.142
  16. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(?) ) in patients with severe haemophilia A. Haemophilia. 2016 Sep; 22(5):730-8.
    View in: PubMed
    Score: 0.132
  17. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0.131
  18. Exploring the biological basis of haemophilic joint disease: experimental studies. Haemophilia. 2012 May; 18(3):310-8.
    View in: PubMed
    Score: 0.095
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.